Mezhdunarodnye rekomendatsii po lecheniyu khronicheskoy krapivnitsy-2012. Chto novogo?
- Authors: Drobik O.S1, Voronova M.Y.1, Goryachkina L.A1
-
Affiliations:
- Issue: No 15 (2013)
- Pages: 49-53
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282371
- ID: 282371
Cite item
Open Access
Access granted
Abstract
Urticaria - a common disease characterized by the appearance of itchy wheals on the skin. Chronic urticarial (CU) is called a state where every day or at least twice a week, for a period of 6 weeks, the blisters appear, each of which has a maximum of 24 hours. The prevalence of chronic urticaria is 0.1 to 0.5 % in the population. The average duration of the disease is 3-5 years. In 50 % of those who have had the disease, may again be worsening even after prolonged remission. In December 2012, a meeting on the initiative of the European Academy of Allergology and Clinical Immunology, to develop recommendations. The aim of these recommendations is to improve the diagnosis and management of patients with urticaria and to promote research and a better understanding of disease.
Full Text
References
- Горячкина Л. А., Ненашева Н. М., Борзова Е.Ю. Крапивница // Лечащий врач. Дерматовенерология 2009. № 3.
- Передельская М.Ю., Дробик О.С., Горячкина Л.А. Возможности терапии хронической рецидивирующей крапивницы омализумабом // Эффективная фармакотерапия 2012. № 1. С. 42-6.
- ODonnel BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136(2):197-201.
- Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy 2012;68:90-6.
- Крапивница и ангиоотек: рекомендации для практикующих врачей. Российский национальный согласительный документ. М., 2007. 127 с.
- Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64.
- Горячкина Л.А., Борзова Е.Ю. Роль хеликобактерной инфекции в патогенезе хронической крапивницы // Аллергология 2004. № 1. С. 31-9.
- Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. Allergy Clin Immunol 2011;128(1):202-09.
- Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. Allergy Clin Immunol 2011;128(3):567-73.
- Данилычева И.В. Крапивница: есть ли проблема? Эффективная фармакотерапия // Аллергология и иммунология 2012. № 2. С. 42-7.
- Борзова Е.Ю. Биомаркеры локального и системного воспаления при хронической крапивнице. Дисс. докт. мед. Наук. М., 2012.
- Barry Kay A., Sun Ying, Mlynek A, et al. Inflammatory cells and Th2 cytokines in chronic spontaneous urticaria, 4ht intenational consensus meeting on urticarial. Berlin, 2012.
- Kocaturk E, Aktas S, Turcoglu Z, et al. Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study. J Dermatol treatment 2011:1-7.
- Никитина И.В. Тарасова М.В., Хроническая крапивница // РЖМ. Дерматология и косметология 2008. № 8. С. 542-47.
Supplementary files
